Edward Lain1, Torsten Skov2, Anders Hall2. 1. Austin Institute for Clinical Research, 302 N Heatherwilde Boulevard #200, Pflugerville, TX, 78660, USA. ted.lain@atxderm.com. 2. LEO Pharma A/S, Ballerup, Denmark.
Abstract
BACKGROUND AND OBJECTIVES:Ingenol disoxate (LEO 43204) is a field therapy in development for the treatment of actinic keratosis (AK) on areas between 25 and 250 cm2. We evaluated the systemic exposure and safety of ingenol disoxate under maximum-use conditions. METHODS: This was a phase I, open-label, non-randomized, multicenter trial. Patients ≥ 18 years of age with ≥ 15 clinically typical, visible, discrete AK lesions in a treatment area on the full face or approximately 250 cm2 on the arm or scalp were treated once-daily for 3 consecutive days with ingenol disoxate 0.018, 0.1, or 0.037% gel, respectively. RESULTS: The trial included 58 patients. Median age (range) of patients was 68 years (42-89) [face, N = 18], 66 years (43-88) [arm, N = 21], and 67 years (37-83) [scalp, N = 19]. The highest quantifiable ingenol disoxate level was observed in the arm group (0.33 nM, area under the concentration-time curve from time zero to the last data point [AUCtlast] 3.12 nM·h). Mean composite local skin response scores peaked at Day 4 and declined towards baseline by Day 15 in all treatment groups. Most adverse events (AEs) were of mild or moderate intensity; the most common treatment-related AEs were application-site pain (face, 88.9%; arm, 57.1%; scalp, 100.0%) and application-site pruritus (face, 50.0%; arm, 52.4%; scalp, 42.1%). CONCLUSION: Very low systemic exposure to ingenol disoxate was observed when applied to the face, arm, or scalp in patients with AK under maximum-use conditions. No new safety signals were identified. TRIAL REGISTRATION: NCT02424305.
RCT Entities:
BACKGROUND AND OBJECTIVES:Ingenol disoxate (LEO 43204) is a field therapy in development for the treatment of actinic keratosis (AK) on areas between 25 and 250 cm2. We evaluated the systemic exposure and safety of ingenol disoxate under maximum-use conditions. METHODS: This was a phase I, open-label, non-randomized, multicenter trial. Patients ≥ 18 years of age with ≥ 15 clinically typical, visible, discrete AK lesions in a treatment area on the full face or approximately 250 cm2 on the arm or scalp were treated once-daily for 3 consecutive days with ingenol disoxate 0.018, 0.1, or 0.037% gel, respectively. RESULTS: The trial included 58 patients. Median age (range) of patients was 68 years (42-89) [face, N = 18], 66 years (43-88) [arm, N = 21], and 67 years (37-83) [scalp, N = 19]. The highest quantifiable ingenol disoxate level was observed in the arm group (0.33 nM, area under the concentration-time curve from time zero to the last data point [AUCtlast] 3.12 nM·h). Mean composite local skin response scores peaked at Day 4 and declined towards baseline by Day 15 in all treatment groups. Most adverse events (AEs) were of mild or moderate intensity; the most common treatment-related AEs were application-site pain (face, 88.9%; arm, 57.1%; scalp, 100.0%) and application-site pruritus (face, 50.0%; arm, 52.4%; scalp, 42.1%). CONCLUSION: Very low systemic exposure to ingenol disoxate was observed when applied to the face, arm, or scalp in patients with AK under maximum-use conditions. No new safety signals were identified. TRIAL REGISTRATION: NCT02424305.
Authors: Marc Bourcier; Linda Stein Gold; Lyn Guenther; Camilla M Andreassen; Johan Selmer; Gary Goldenberg Journal: J Dermatolog Treat Date: 2017-04-04 Impact factor: 3.359
Authors: Alicia D Bucko; Michael Jarratt; Dowling B Stough; Laerke Kyhl; John Villumsen; Anders Hall Journal: J Dermatolog Treat Date: 2017-05-25 Impact factor: 3.359
Authors: Mark Lebwohl; Neil Swanson; Lawrence L Anderson; Anita Melgaard; Zhenyi Xu; Brian Berman Journal: N Engl J Med Date: 2012-03-15 Impact factor: 91.245
Authors: Eggert Stockfleth; Ketty Peris; Carlos Guillen; Rino Cerio; Nicole Basset-Seguin; Peter Foley; José Sanches; Alex Culshaw; Sandra Erntoft; Mark Lebwohl Journal: Int J Dermatol Date: 2015-04-10 Impact factor: 2.736